Ayala Pharmaceuticals is a clinical-stage biotechnology company focused on the development of innovative immunotherapies for cancer. The company’s core technology leverages a proprietary attenuated Listeria monocytogenes–based platform to deliver tumor-associated antigens directly to antigen-presenting cells, stimulating potent T-cell responses. By harnessing the body’s own immune system, Ayala aims to achieve durable anti-tumor activity while maintaining a favorable safety profile.
The company’s pipeline comprises several lead candidates targeting a variety of solid tumors. Among these is ADXS-HPV, an immunotherapy designed to treat human papillomavirus–associated cervical cancer, which has advanced into late-stage clinical trials. Ayala is also developing ADXS-NEO, a personalized neoantigen therapy tailored to individual patient tumor profiles, and ADXS-PSA for prostate cancer. These programs reflect the company’s commitment to addressing both virus-driven and mutation-driven malignancies.
Founded in the late 2000s under the name Advaxis, the company rebranded as Ayala Pharmaceuticals to underscore its evolution and expanded therapeutic focus. Headquartered in Princeton, New Jersey, Ayala conducts research and clinical operations across the United States and collaborates with academic and research institutions to advance its immunotherapy candidates. The company’s strategic alliances aim to accelerate clinical development and broaden access to its novel therapies.
Ayala’s leadership team brings together seasoned executives and scientific experts in oncology, immunology, and biopharmaceutical development. The company remains dedicated to translating its Listeria-based platform into meaningful treatments for patients with hard-to-treat cancers, leveraging its expertise to address unmet medical needs in the global oncology community.
AI Generated. May Contain Errors.
